AzTrials
AzTrials

AnemiaQFSNCT03853304

Quadruple Fortified Salt Trial in India

A study testing + Folic acid, + Vitamin B12 and DFS in people with Anemia and Folate Deficiency, run by Cornell University at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Women of reproductive age are at an increased risk of anemia and micronutrient deficiencies. Evidence supports the role of periconceptional nutrition in the development of neural tube defects and other pregnancy complications. Read more about this study

Who is it for?
Ages 18 to 49 years, women onlyHealthy volunteers can take part
Conditions the study is for
Anemia, Folate Deficiency, Vitamin B 12 Deficiency
What is being tested?
+ Folic acid, + Vitamin B12 and DFS
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,000 participants
Where
1 siteIndia
Study dates
1 Oct 2023to Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 49 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Women between 18 and 49 years of age
  • Healthy
  • Not pregnant or lactating
  • Plan to reside in the catchment area of our periconceptional surveillance program for at least two years

Who cannot join

  • Severe anemia (Hemoglobin <8.0 g/dL)
  • Reported diagnosis of HIV, malaria infection, or active tuberculosis disease
  • Malabsorption disorders (i.e., medical conditions that may affect vitamin B12 absorption or metabolism)
  • Stage 2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg)
  • Glycated hemoglobin (HbA1c) ≥6.5%
  • Other serious pre-existing medical conditions (e.g., defined as the need for regular medication use), active infections, or acute illnesses
Show all 10Show fewer
  • Previous pregnancy affected by a neural tube defect (i.e., who have had a fetus diagnosed as affected by a neural tube defect or have given birth to a baby with a neural tube defect) (will be referred to OB/GYN for standard of care, including folic acid supplementation, and excluded)
  • Planning to become pregnant (or planning to have a child) in the next 12 months (will be referred to OB/GYN for standard of care, including folic acid supplementation, and be excluded)
  • Daily micronutrient supplements (i.e., tablets, capsules, dispersible tablets; ≥4 times in the past week)
  • Intramuscular or intravenous interventions containing medications or micronutrients (e.g., iron, vitamin B12, folic acid) in the past 3 months

Trial locations and contacts

1 site in 1 country.

India1 site
  • Arogyavaram Medical Centre

    Madanapalle, Andhra Pradesh

Other trials in India

About this study

Official title: A Randomized Trial of Quadruple Fortified Salt for Anemia and Birth Defects Prevention in Southern India

Women of reproductive age are at an increased risk of anemia and micronutrient deficiencies. Evidence supports the role of periconceptional nutrition in the development of neural tube defects and other pregnancy complications. Vitamin B12 deficiency is a risk factor for neural tube defects and may modify folate biomarkers that predict neural tube defect risk at the population level. There is an interest in mandatory fortification with vitamin B12 and folic acid for anemia and birth defect prevention. However, there are limited population-representative data needed to inform policy and guidelines. This randomized trial will be conducted to evaluate the efficacy of quadruple-fortified salt (QFS; iron, iodine, folic acid, vitamin B12) in 1,000 women and their households in Southern India.

Read the detailed description

Women of reproductive age are at increased risk for anemia and micronutrient deficiencies, due in part to social structures and increased nutritional requirements across the conceptional period. Anemia is an important public health problem and has been associated with risk of adverse pregnancy outcomes, including maternal and infant mortality, preterm delivery, and low birth weight. Iron deficiency is the leading cause of anemia worldwide, accounting for 20% to half of the anemia cases. Deficiencies in folate and/or vitamin B12 also result in megaloblastic anemia, and inadequate periconceptional folate and vitamin B12 status have been linked to pregnancy complications, including birth defects.

Neural tube defects are among the most common and debilitating birth defects in the United States and globally. Neural tube defects are structural birth defects that arise when the neural folds fail to fuse entirely during early embryogenesis. It is estimated that there are over 260,000 cases of neural tube defects per year globally, ranging from 1 to 80 per 10,000 births, with higher prevalence in low- and middle-income countries. India has one of the highest burdens of neural tube defects in the world, accounting for over one-third of all neural tube defects globally.

The links between maternal folate status and neural tube defect risk in offspring have been well established. In randomized trials, periconceptional folic acid supplementation reduced the risk of neural tube defects by approximately 70%. Fortification of staple foods with folic acid is one of the most efficacious and cost-effective public health interventions and has been linked to decreased neural tube defects in national folic acid fortification programs. Fortification interventions to date have primarily targeted wheat (and maize) flour, which are not primary staples in some settings with the highest burden of neural tube defects, such as Southern India and China.

There is increasing interest in fortification strategies targeting additional staple foods and micronutrient deficiencies in at-risk populations. Emerging evidence suggests that vitamin B12 deficiency is associated with an increased risk of neural tube defects independent of folate status and may modify red blood cell folate concentrations which are used to predict risk of neural tube defects at the population level. In Southern India, the setting of this randomized trial, rice is the primary staple and folic acid fortification is not currently mandatory. Findings from a recently completed population-based pre-intervention biomarker survey in this setting demonstrated a substantial burden of anemia and micronutrient deficiencies of iron, vitamin B12, and folate in women of reproductive age. Together, these findings underscore the potential benefits of developing additional fortification strategies to deliver folic acid and other micronutrients for prevention of anemia and neural tube defects.

Salt fortification is a promising strategy to prevent multiple micronutrient deficiencies, as it is widely consumed, affordable, and has existing production and distribution systems. In India, salt is one of the most widely consumed and fortifiable foods, and double-fortified salt (i.e., with iron and iodine) is included in the national fortification guidelines and social safety net programs in India for prevention of anemia and iron deficiency. Randomized trials demonstrated that double-fortified salt significantly improved serum ferritin or iron deficiency in women of reproductive age and school children. Findings from meta-analyses suggest that double-fortified salt improves hemoglobin concentrations and decreases risk of anemia; however, findings from double-fortified salt trials in India for anemia have been heterogeneous. For example, in a randomized trial of double-fortified salt among Indian female tea pickers by Haas et al., double-fortified salt improved hemoglobin, serum ferritin, total body iron, and soluble transferrin receptor levels, compared with iodized salt without iron, after adjusting for the respective baseline bio- markers. However, the prevalence of anemia (53%) as well as vitamin B12 (37%) and folate (86%) deficiencies remained high at endpoint. These findings highlight the need to develop additional interventions to target other nutritional causes of anemia and multiple micronutrient deficiencies (i.e., vitamin B12 and folate).

Recent technological advances informed the development of a quadruple-fortified salt - i.e., iodine, iron, folic acid, and vitamin B12, which can be adjusted to the level of salt intake in populations. Quadruple-fortified salt has undergone preliminary testing for organoleptic properties and consumer acceptability and is ready for use in randomized efficacy trials in human populations.

The objective of this randomized trial is to evaluate the efficacy of quadruple-fortified salt-i.e., iodine, iron, folic acid, and vitamin B12-on improving 1) hemoglobin, 2) red blood cell folate and serum folate, and 3) vitamin B12 concentrations, among women of reproductive age in Southern India.

Being tested
+ Folic acid, + Vitamin B12, DFS
Medical subject headings
Anemia, Folic Acid Deficiency, Vitamin B 12 Deficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • + Folic acidOther

    Salt fortified with folic acid

  • + Vitamin B12Other

    Salt fortified with vitamin B12

  • DFSOther

    Salt fortified with iron and iodine

Study groups in NCT03853304
Study groupRoleWhat they receive
Quadruple-Fortified Salt (QFS)ExperimentalSalt fortified with iron, iodine, folic acid, and vitamin B12
Receives: Other: + Folic acid; Other: + Vitamin B12; Other: DFS
DFS + Folic acidExperimentalSalt fortified with iron, iodine, and folic acid
Receives: Other: + Folic acid; Other: DFS
DFS + Vitamin B12ExperimentalSalt fortified with iron, iodine, and vitamin B12
Receives: Other: + Vitamin B12; Other: DFS
Double-fortified salt (DFS)Active comparatorSalt fortified with iron and iodine
Receives: Other: DFS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concentrations of erythrocyte folate and serum folate

    Erythrocyte folate and serum folate concentrations, nmol/L

    Measured: Endpoint (12 months)

  2. Concentrations of hemoglobin

    Hemoglobin concentrations, g/dL

    Measured: Endpoint (12 months)

  3. Concentrations of vitamin B12

    Vitamin B12 concentrations, pmol/L

    Measured: Endpoint (12 months)

Secondary outcomes (3)
  1. Folate deficiency and insufficiency

    Erythrocyte (RBC) folate <305.0 nmol/L; <748.0 nmol/L

    Measured: Endpoint (12 months)

  2. Anemia

    Hemoglobin <12.0 g/dL

    Measured: Endpoint (12 months)

  3. Vitamin B12 deficiency and insufficiency

    Total vitamin B12 <148.0 pmol/L; <221.0 pmol/L

    Measured: Endpoint (12 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2019
  2. Study start1 Oct 2023
  3. Primary completionDec 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Factorial
Model description
After confirming eligibility and informed consent/assent, women will be randomly assigned to one of the 4 intervention arms, using a 2 X 2 factorial design: 1. Quadruple-fortified salt (QFS; i.e., iron, iodine, folic acid, and vitamin B12) 2. DFS + folic acid 3. DFS + vitamin B12; and 4. Double-fortified salt (DFS; i.e., iron and iodine)
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03853304
Sponsor's protocol ID
86613
Acronym
QFS
Status last verified
Mar 2024
First submitted
22 Feb 2019
Last updated
1 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Williams JL, Bonam W, Crider KS. Anemia and Vitamin B-12 and Folate Status in Women of Reproductive Age in Southern India: Estimating Population-Based Risk of Neural Tube Defects. Curr Dev Nutr. 2021 Apr 26;5(5):nzab069. doi: 10.1093/cdn/nzab069. eCollection 2021 May.

    PubMed 34027296
  • Finkelstein JL, Fothergill A, Johnson CB, Guetterman HM, Bose B, Jabbar S, Zhang M, Pfeiffer CM, Qi YP, Rose CE, Krisher JT, Ruth CJ, Mehta R, Williams JL, Bonam W, Crider KS. Periconceptional surveillance for prevention of anaemia and birth defects in Southern India: protocol for a biomarker survey in women of reproductive age. BMJ Open. 2020 Oct 29;10(10):e038305. doi: 10.1136/bmjopen-2020-038305.

    PubMed 33122315
  • Finkelstein JL, Guetterman HM, Fothergill A, Johnson CB, Qi YP, Jabbar S, Zhang M, Pfeiffer CM, Rose CE, Yeung LF, Williams JL, Krisher JT, Ruth C, Roy Choudhury D, Venkatramanan S, Haas JD, Kuriyan R, Mehta S, Bonam W, Crider KS. A Randomized Trial of Quadruple-Fortified Salt for Anemia and Birth Defects Prevention in Southern India: Protocol Design and Methods. Curr Dev Nutr. 2023 Feb 21;7(3):100052. doi: 10.1016/j.cdnut.2023.100052. eCollection 2023 Mar.

    PubMed 37181934
  • Finkelstein JL, Fothergill A, Guetterman HM, Johnson CB, Bose B, Qi YP, Rose CE, Williams JL, Mehta S, Kuriyan R, Bonam W, Crider KS. Iron status and inflammation in women of reproductive age: A population-based biomarker survey and clinical study. Clin Nutr ESPEN. 2022 Jun;49:483-494. doi: 10.1016/j.clnesp.2022.02.123. Epub 2022 Mar 5.

    PubMed 35623855
  • Guetterman HM, Rajagopalan K, Fox AM, Johnson CB, Fothergill A, George N, Krisher JT, Haas JD, Mehta S, Williams JL, Crider KS, Finkelstein JL. A Randomized Crossover Trial of Acceptability of Quadruple-Fortified Salt in Women and their Households in Southern India. J Nutr. 2025 Jan;155(1):322-337. doi: 10.1016/j.tjnut.2024.10.037. Epub 2024 Oct 26.

    PubMed 39490799

Questions about this trial

What is this clinical trial studying?

A study testing + Folic acid, + Vitamin B12 and DFS in people with Anemia and Folate Deficiency, run by Cornell University at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concentrations of erythrocyte folate and serum folate (time frame: Endpoint (12 months)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03853304, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in